



RELIABLE AND COST EFFECTIVE SOLUTIONS
FOR DRUG DISCOVERY TO DEVELOPMENT



COMMONWEALTH BIOTECHNOLOGIES, INC.
OVERVIEW

Commonwealth Biotechnologies, Inc., was founded in 1992 to provide sophisticated research and development support services on a fee-for-service basis to the global biotechnology and pharmaceutical industry. Since 2004, CBI has pursued a strategy of acquiring or merging with complementary companies that extend its drug discovery capabilities and earnings potential.

CBI now operates four distinct business units and one joint venture and collectively employs over 140 staff in world-class laboratories based the U.S, U.K and Australia:

- **CBI Services**, a discovery phase contract research organization.
- **Exelgen**, a medicinal and synthetic chemistry company.
- **Fairfax Identity Laboratories**, a DNA reference business.
- **Mimotopes**, a peptide and discovery chemistry business.
- **Venturepharm-Asia**, a joint venture establishing a premiere contract research organization.

CBI Services

CBI Services provides a wide array of life-science solutions in the areas of bio-defense, laboratory support and contract research. CBI has broad expertise in the most current analytical chemistries, microbiology applications and molecular biology technologies and has a reputation as a provider of novel and imaginative research and development solutions. CBI offers all services under the FDA's Good Laboratory Practices (GLP) Guidelines as codified in 21CFR 58. Selected Services are also offered under the FDA's Good Manufacturing Practices (cGMP) and Good Clinical Practices (cCMP) guidelines. The Quality Assurance office manages all regulated services.

Exelgen

Exelgen has extensive experience in medicinal chemistry, computational design as well as high-throughput chemical synthesis, analysis and purification. Exelgen's competitive advantage lies in its unique ability to combine these offerings, particularly its proprietary informatics systems with state-of-the-art medicinal chemistry research. Exelgen's business can be broadly grouped into three categories: off the shelf and custom made compound libraries; screening, purification and quantitation services; and Screening collections and early stage in-licensing.

Commonwealth
Biotechnologies, Inc.

CORPORATE
INFORMATION

CBI Services

CORE BIOLOGY &
BIOCHEMISTRY

Exelgen

DISCOVERY
CHEMISTRY &
COMPOUNDS

Fairfax Identity
Laboratories

GENETIC TESTING
& IDENTIFICATION

Mimotopes

PEPTIDE CHEMISTRY
& DISCOVERY

Venturepharm-
ASIA

JOINT VENTURE,
CHINA CRO

Fairfax Identity Laboratories (FIL)

FIL has been at the forefront of DNA technology of profiling for identity since it open it's doors in 1990. FIL's rigorous standards guarantee beyond a reasonable doubt the credible evidence that clients demand. Their results affect decisions regarding criminal trials, paternity, immigration, estate settlement, adoption, and other issues of identity. FIL provides state of the art forensics, paternity and CODIS services to government and private concerns.

Mimotopes Pty., Ltd.

Mimotopes is an industry leader with over 16 years experience in the development, synthesis and distribution of research grade peptides for the drug discovery industry. Mimotopes' patented synthesis technologies, state-of-the-art facilities and highly educated and experienced staff make it one of the leading research grade peptide synthesis companies in the world. Mimotopes' products and services are delivered to commercial clients on a fee-for-service basis (80%) and to discovery partners on a cost-recovery basis and IP sharing basis (20%). In 2006, Mimotopes developed a significant relationship with Genzyme Pharmaceuticals for the production of cGMP grade peptides, further extending the reach of Mimotopes' capabilities.

Venturepharm-Asia

In May 2008, Commonwealth Biotechnologies, Inc., (CBI), and Venturepharm Laboratories, Ltd., (VPL), announced a joint venture to establish one of the largest premiere contract research organizations in the world providing end-to-end discovery, development and clinical research capabilities.

The Joint Venture brings together the best of what the East and the West offer in the pharmaceutical outsourcing industry by providing rapid, secure, high quality, and innovative services at globally competitive prices.

Find out more at www.commonwealthbiotech.com.

Contact in North America & Asia

Mark G. Hober
VP Business Development
Commonwealth Biotechnologies, Inc.
601 Biotech Dr.
Richmond, VA 23235
United States
mhober@exelgen.com
PH: 925-283-6260

Contact in Europe

Mark Warne
Managing Director
Exelgen, Ltd.
Bude-Stratton Business Park
Bude, Cornwall EX23 8LY
United Kingdom
mwarne@exelgen.com
PH: +44 (0) 1288 357404



With more than 100 experts in offices throughout the world, CBI offers cutting-edge research and development products and services to the global life sciences industry. The CBI group operates through four business units and a Joint Venture:

CBI Services offers molecular biology, protein chemistry, bio-analytical services.
www.cbi-biotech.com

Exelgen provides medicinal and computational discovery chemistry services.
www.exelgen.com

Fairfax Identity Laboratories is a DNA reference laboratory providing genetic testing.
www.fairfaxidlab.com

Mimotopes delivers peptide and discovery chemistry capabilities.
www.mimotopes.com

Venturepharm-Asia is a joint venture establishing a world-class CRO.
www.venturepharm.com

Further Information on CBI is available at www.commonwealthbiotech.com.